Go to Homepage

United States

|

Our achievements

A long tradition of innovation

We’ve been in the business of therapeutic innovation for over 117 years. Over that time, we’ve passed milestone after milestone. Our establishment as a standalone business in 2020 further increased our capability and focus as a producer of specialist therapeutics in neurology and beyond.

Some of our proudest and most significant accomplishments are detailed below.

OUR HISTORY AT
A GLANCE

Merz Therapeutics North America opens newly expanded office in Raleigh, N.C.

Phase III program commences investigating XEOMIN® as treatment for migraine prevention

Merz Therapeutics’ portfolio expands with the acquisition of INBRIJA® and (F)AMPYRA® from Acorda Therapeutics

XEOMIN® is approved in the U.S. as treatment for chronic sialorrhea (pediatric) and upper limb spasticity (pediatric)

Merz Therapeutics is established as an independently operating therapeutics business within the Merz Group

XEOMIN® is approved in the U.S. as first-line treatment for adults with blepharospasm

XEOMIN® is approved in the U.S. as treatment for chronic sialorrhea (adults with excessive drooling)

Merz Therapeutics North America moves headquarters to Raleigh, N.C.

XEOMIN® is approved in the U.S. as treatment for upper limb spasticity (adults)

Radiesse® Voice relaunches as ProlarynTM injectable implants treating vocal fold insufficiency

Merz Therapeutics acquires Cuvposa® from Shionogi Inc. for chronic severe drooling in pediatric patients with neurological conditions

XEOMIN® is approved in the U.S. as treatment for cervical dystonia (adults) and blepharospasm

Merz Therapeutics North America opens in Greensboro, N.C., through acquisition of Mayrand Pharmaceuticals

You might also like

Contact Icon

U.S. General Inquiries

919-582-8000 merztherapeutics@merz.com

U.S. Human Resources

merztherapeutics@merz.com

U.S. Customer service

1-855-463-7989 therapeuticorders@merz.com

Global Corporate development

Platform change – You are leaving this page.

You are leaving this website. With respect to the content of the following page, as well as to links to other websites located on this page, Merz Therapeutics U.S. has no way of controlling the content of these sites. Merz Therapeutics U.S. assumes no responsibility for the content of these sites or the consequences of their use by visitors. However, we ask you to notify us immediately of any illegal content on the linked sites.

Continue to url

Change of country – You are leaving this page.

You are leaving this website. The content of the following sites maintained by the parent company or another affiliated company, or links to other sites located on this site, is subject to the legal requirements of the country in which the site is maintained. Merz Therapeutics U.S. accepts no responsibility whatsoever for the content of these websites or for the consequences of their use by visitors. However, we ask you to notify us immediately of any illegal content on the linked sites.

Continue to url